GET DAILY SIGNALSMicrobot Medical (MBOT) Faces Wide Analyst Targets With +415% Upside to $5.40
Key Takeaways
- The central price target of $5.40 is the arithmetic mean of four verified, current analyst price targets reviewed for Microbot Medical Inc. (MBOT).
- With shares trading near $1.05, reaching $5.40 would require a gain of roughly 415% — a very large move.
- Individual analyst targets range from $2.50 to $12.00, an unusually wide spread that reflects extreme disagreement about the company's early-stage commercial ramp.
- The strongest supporting factors are the FDA-cleared LIBERTY robotic system, first-ever revenue, and triple-digit sequential growth in the company's early launch.
- The biggest risks are minimal revenue today, ongoing cash burn, execution uncertainty, and potential shareholder dilution for a company that is not yet profitable.
- You can read more about this ticker's Major News, Today's Price Move, Forecast, and Earnings on additional pages.
- Explore Trending AI Robots to see AI-driven trading strategies applied across the market.
Analyst Price Targets and Consensus View
Microbot Medical Inc. (MBOT) is a commercial-stage medical device company developing the LIBERTY Endovascular Robotic System — the first FDA-cleared, single-use, remotely operated robotic platform for peripheral endovascular procedures. Four current analyst targets were reviewed for this analysis, spanning roughly $2.50 to $12.00. The arithmetic mean of these targets is about $5.38, which rounds to the $5.40 central target used here.
The wide range is itself the key signal. H.C. Wainwright analyst Raghuram Selvaraju maintains a $12 target (reiterated in late October 2026), while Citizens JMP's Daniel Stauder initiated coverage with a much more conservative $2.50 target. Between them sit Lucid Capital's Alex Nowak at $3 (lowered from $4 in September 2026) and B. Riley's William Wood at $4. That $12 figure meaningfully pulls the average higher; excluding it, the remaining three targets average only about $3.20. Analysts generally agree the product is differentiated and the direction is positive, but they disagree sharply on how quickly hospitals will adopt it and how fast revenue can scale. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Current Market Position and Path Toward the Target
With MBOT trading near $1.05, a move to $5.40 represents roughly 415% upside — a very large required move by any measure. The company recorded its first revenue in the first quarter of 2026 during its Limited Market Release and has since transitioned to a Full Market Release, reporting that second-quarter revenue and customer growth each rose more than 100% sequentially. Even so, these figures are starting from a very low base, and the company is not yet profitable, with a fiscal-year EPS forecast still negative.
A path toward the target would depend on sustained commercial adoption across U.S. sales territories, expansion of repeat orders, and international regulatory progress. The valuation today rests almost entirely on future growth expectations rather than current earnings, which is why even a modest execution setback can move the shares dramatically.
What Could Support a Move Toward the Target
- Differentiated, capital-light product: LIBERTY's single-use, disposable design avoids the high upfront capital cost of traditional robotic systems, a selling point analysts cite as lowering adoption barriers.
- Early commercial momentum: Accounts have expanded across multiple U.S. states, including two pivotal clinical-trial sites, with repeat orders reported as utilization grows.
- Government distribution channel: An agreement with Lovell Government Services opens access to more than 2,000 federal healthcare facilities, including VA and Department of Defense sites.
- International expansion: Israel granted marketing clearance in mid-2026, and the company is pursuing a CE Mark to enter European markets.
- Manufacturing capacity: A second manufacturing site with Sanmina is being established to support anticipated demand and cost-reduction efforts.
What Could Prevent the Target From Being Reached
- Extremely small revenue base: Lucid Capital has flagged that near-term 2026 figures remain modest, limiting visible proof points during early commercialization.
- Adoption and execution risk: B. Riley has cited slower LIBERTY adoption tied to system-level approval processes, underscoring that hospital purchasing cycles can lag.
- Cash burn and dilution: As a pre-profit company, MBOT may need additional financing, which could dilute existing shareholders.
- Wide target dispersion: The gap between a $2.50 and a $12 target reflects genuine uncertainty, meaning the $5.40 average should not be read as a precise or guaranteed outcome.
- Competition and sentiment: The endovascular robotics field is competitive, and small-cap medical technology names can fall sharply on any negative clinical, regulatory, or funding news.
Technical Levels and Market Structure
As a low-priced micro-cap that only recently began generating revenue, MBOT trades just above the $1.00 psychological whole-dollar level, and durable support and resistance zones are difficult to establish given the short commercial history. The stock's extreme analyst-target dispersion is consistent with a high-volatility, early-stage profile in which conventional technical levels carry less weight than fundamental and funding developments.
Time Horizon and What Investors Should Monitor
Analyst price targets typically reflect a roughly 12-month research horizon, though the actual time frame varies by firm and is not always disclosed. Investors should watch quarterly revenue and customer-growth trends, the pace of new account additions and repeat orders, progress toward a European CE Mark, any additional financing announcements, and analyst target revisions. Guidance around cash runway and gross-margin improvement will be particularly important for a company transitioning from limited to full commercial launch.
Using AI Tools for Additional Perspective
For traders tracking a volatile, early-stage name like this, Tickeron's AI Daily Buy/Sell Signals offer a data-driven complement to fundamental research. The system uses artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. Traders can use these signals to discover opportunities, monitor existing positions, and spot shifting trends more efficiently than manual scanning allows, making it a practical tool for navigating fast-moving situations.
Final Assessment
Whether MBOT can reach $5.40 hinges on a very large, roughly 415% move that would require the company to convert early commercial momentum into sustained, meaningful revenue growth. The $5.40 figure is a simple average of four analyst targets spanning $2.50 to $12.00 — a spread so wide that it signals more disagreement than conviction. Bulls emphasize the differentiated, capital-light LIBERTY platform and early adoption traction; bears emphasize the tiny revenue base, cash burn, and execution risk. The realistic near-term milestone is not the $5.40 average but continued sequential revenue growth and margin improvement. Investors should monitor quarterly results, account and order trends, international approvals, and funding activity rather than treat the average target as a forecast.
Exploring Tickeron AI Daily Buy/Sell Signals
In my own research on names like this, I find Tickeron’s AI Daily Buy/Sell Signals helpful for layering quantitative signals on top of the fundamentals. The tool scans a broad universe in real time and flags shifts that might otherwise require constant manual review, which can be especially useful during periods of high volatility or when waiting on quarterly updates. It is not a substitute for deep analysis but serves as one more data point when forming an overall view.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
MBOT's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for MBOT turned positive on October 22, 2026. Looking at past instances where MBOT's MACD turned positive, the stock continued to rise in 43 of 48 cases over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where MBOT's RSI Indicator exited the oversold zone, 24 of 32 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 75%.
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on MBOT as a result. In 75 of 88 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 85%.
Following a +9.62% 3-day Advance, the price is estimated to grow further. Considering data from situations where MBOT advanced for three days, in 150 of 205 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 39 of 45 cases where MBOT's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 87%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MBOT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
MBOT broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for MBOT entered a downward trend on November 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 12 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating fairly steady price growth. MBOT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 93 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.082) is normal, around the industry mean (4.142). P/E Ratio (-4.440) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (263.158) is also within normal values, averaging (40.124).
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MBOT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company, which specializes in the research, design, development and commercialization of micro-robotics assisted medical technologies
Industry MedicalNursingServices
Advertisement